Welcome to our dedicated page for Lite Strategy news (Ticker: LITS), a resource for investors and traders seeking the latest updates and insights on Lite Strategy stock.
Lite Strategy, Inc. (NASDAQ: LITS) generates news at the intersection of digital assets and pharmaceutical preparations. The company identifies itself as the first U.S.-listed public company to adopt Litecoin (LTC) as its primary reserve asset, while continuing to evaluate a legacy portfolio of oncology-focused drug candidates. Its news flow reflects both its transformation from MEI Pharma and its ongoing activities in digital asset treasury management and capital markets.
On this page, readers can follow company announcements related to Lite Strategy’s Litecoin-based treasury strategy, including disclosures about LTC acquisitions, treasury structure, and partnerships. The company has highlighted a strategic relationship with GSR, a crypto investment firm that advises on its digital asset treasury strategy and supports governance, execution, and market expertise. News items also cover governance developments, such as board changes and executive appointments, along with equity compensation decisions reported in SEC filings.
Lite Strategy’s press releases and updates also address capital market actions, such as the authorization of a share repurchase program and the use of private placement offerings and pre-funded warrants to raise capital. In addition, the company provides updates on its remaining pharmaceutical assets, including the sale of ME-344 (now WE-868) to Aardvark Therapeutics and its evaluation of future options for voruciclib and zandelisib.
Investors, analysts, and observers can use this news feed to monitor how Lite Strategy executes its Litecoin-focused treasury strategy, manages its capital structure, and advances or monetizes its legacy drug candidates. Regularly reviewing this page helps track key developments in the company’s evolving business model and corporate identity.
Lite Strategy (Nasdaq: LITS) reported fiscal 2026 second quarter results for the period ended December 31, 2025, highlighting the launch of active treasury operations. The company generated approximately $600,000 in gross premiums from a new covered‑call program, started a $25 million share repurchase plan, and held $8.8 million in cash.
Management said proceeds from treasury operations funded the repurchase program and noted initiation of pre‑clinical pharmaceutical R&D as a potential monetization pathway.
Lite Strategy (NASDAQ: LITS) reported first quarter fiscal 2026 results and outlined a strategic pivot to a Litecoin-based digital asset treasury. Key actions include a $100 million PIPE raised in July 2025, the acquisition of 929,548 LTC tokens as a primary reserve asset, a strategic partnership with GSR, and a rebrand from MEIP to LITS with a new ticker and website.
The company also announced a $25 million share repurchase program, reported $12.21 million in working capital and no outstanding debt, and completed the sale of its clinical asset ME-344 (WE-868) to Aardvark Therapeutics.
Lite Strategy (NASDAQ: LITS) announced on October 29, 2025 that its Board authorized a $25 million share repurchase program effective immediately. The program permits open-market and negotiated buybacks and may be executed under a future Rule 10b5-1 trading plan to allow purchases outside normal trading windows. The company said repurchases will be funded from available working capital and that timing and amounts will depend on market conditions; the program has no set price targets or timetable and may be suspended or terminated. Management highlighted flexibility to buy shares when trading below mNAV and to sell via its at-the-market offering when shares trade at a premium to mNAV.
Lite Strategy (NASDAQ: LITS) marked the 14th anniversary of Litecoin on October 16, 2025, highlighting Litecoin’s longevity as the second-longest-running blockchain and its transaction history.
Lite Strategy says it is the first U.S.-listed public company to adopt Litecoin as its primary reserve asset, positioning LITS as a regulated, public-market vehicle for institutional exposure to Litecoin. Management frames the move as an immediate alternative while some digital asset ETFs remain pending amid an ongoing government shutdown.
MEI Pharma (NASDAQ:MEIP) announced its corporate rebranding to Lite Strategy, Inc. and will change its ticker to LITS effective September 11, 2025. The transformation reflects the company's strategic pivot to digital asset treasury management, focusing on Litecoin (LTC) as its primary reserve asset.
The company has already secured over $100 million in LTC with guidance from Litecoin creator Charlie Lee, who serves on the board, and GSR Ventures. While embracing this new direction, Lite Strategy continues to maintain its pharmaceutical pipeline, evaluating development opportunities for voruciclib and zandelisib.